Reversal In CAR-T Patent Battle Shows Federal Circuit’s Preference For Narrow Claims

Appeals court finds that Juno/BMS patent is invalid, overturning $1.2bn jury verdict against Kite/Gilead. Ruling illustrates court does not like functionally-defined patent claims, attorneys say. Decision could impact future CAR-T patents and disputes.

CAR T-cell immunotherapy
Gilead wins reversal in CAR T-cell immunotherapy patent battle • Source: Alamy

More from Cell & Gene Therapies

More from Advanced Technologies